Corporate Updates: Stellantis Faces H1 Loss, AstraZeneca’s Lung Cancer Drug Shows Promise, Roche’s COPD Drug Mixed
Key Takeaways Stellantis (STLA) reported preliminary Q2 shipments down 6% year-over-year to 1.4 million units, with North American shipments plummeting […]
